Discarded donor livers to be maintained in Liver ICU in USA by Ochre Bio to discover new therapies
Business Wire - 11-May-2022Liver ICU main aim-Improve liver transplant processes and discover therapies for liver diseases
Jack O’Meara
Co-founder and CEO at Ochre Bio
Jack O’Meara is co-founder and CEO of Ochre Bio. Ochre develops genomic medicines that rejuvenate transplanted livers, and ultimately hopes to treat fatty liver disease (NASH/NAFL) and other metabolic diseases. Ochre employs spatial sequencing, advanced genomics, and high-throughput screening to identify disease-causing genes and develops combination therapies which are tested in donor livers kept alive outside of the body. Jack is a biomedical engineer by training, with a background in bringing new healthcare innovations to market. His career spans management consulting, company creation, health technology and biopharma market launches. He has a BEng from National University of Ireland, Galway, and MSc from the University of Notre Dame.
Visit website: https://www.ochre-bio.com/team/jack-o-meara/
See also
Details last updated 27-Aug-2022
Jack O’Meara News
Jack O’Meara is also referenced in the following:
AI for Longevity Summit and Hackathon
30-May-2025
Collaboration between scientist, doctors and engineers to understand ageing (London, UK)
